Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shandong Lukang Pharmaceutical Co Ltd announces FY 2013 net profit outlook


Friday, 24 Jan 2014 07:00pm EST 

Shandong Lukang Pharmaceutical Co Ltd:Sees net profit for the fiscal year (FY) 2013 to be 7 million yuan - 11 million yuan), compared to the net profit of the same period in FY 2012 (-133,834,252.34 yuan).Says the reason for positive outlook is due to the cost reduction, the investment profit and the receiving of government subsidies. 

Company Quote

8.84
-0.3 -3.28%
19 Dec 2014